These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37098529)

  • 1. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.
    Lachmann RH; Diaz GA; Wasserstein MP; Armstrong NM; Yarramaneni A; Kim Y; Kumar M
    Orphanet J Rare Dis; 2023 Apr; 18(1):94. PubMed ID: 37098529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results.
    Diaz GA; Giugliani R; Guffon N; Jones SA; Mengel E; Scarpa M; Witters P; Yarramaneni A; Li J; Armstrong NM; Kim Y; Ortemann-Renon C; Kumar M
    Orphanet J Rare Dis; 2022 Dec; 17(1):437. PubMed ID: 36517856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
    Wasserstein MP; Diaz GA; Lachmann RH; Jouvin MH; Nandy I; Ji AJ; Puga AC
    J Inherit Metab Dis; 2018 Sep; 41(5):829-838. PubMed ID: 29305734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
    Wasserstein MP; Lachmann R; Hollak C; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Hennermann JB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Thurberg BL; Yarramaneni A; Armstrong NM; Kim Y; Kumar M
    Orphanet J Rare Dis; 2023 Dec; 18(1):378. PubMed ID: 38042851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
    Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
    Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
    Wasserstein M; Lachmann R; Hollak C; Arash-Kaps L; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Chen Y; Furey S; Thurberg BL; Zaher A; Kumar M
    Genet Med; 2022 Jul; 24(7):1425-1436. PubMed ID: 35471153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
    Syed YY
    Clin Drug Investig; 2023 May; 43(5):369-377. PubMed ID: 37133675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency.
    Raebel EM; Wiseman S; Donnelly C; Mathieson T; Pountney J; Crowe J; Hopkin J
    Orphanet J Rare Dis; 2024 Feb; 19(1):36. PubMed ID: 38303068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.
    Thurberg BL; Diaz GA; Lachmann RH; Schiano T; Wasserstein MP; Ji AJ; Zaher A; Peterschmitt MJ
    Mol Genet Metab; 2020; 131(1-2):245-252. PubMed ID: 32620536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.
    Diaz GA; Jones SA; Scarpa M; Mengel KE; Giugliani R; Guffon N; Batsu I; Fraser PA; Li J; Zhang Q; Ortemann-Renon C
    Genet Med; 2021 Aug; 23(8):1543-1550. PubMed ID: 33875845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency).
    McGovern MM; Wasserstein MP; Kirmse B; Duvall WL; Schiano T; Thurberg BL; Richards S; Cox GF
    Genet Med; 2016 Jan; 18(1):34-40. PubMed ID: 25834946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
    Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
    Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olipudase Alfa: First Approval.
    Keam SJ
    Drugs; 2022 Jun; 82(8):941-947. PubMed ID: 35639287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.
    Garside B; Ho JH; Kwok S; Liu Y; Dhage S; Donn R; Iqbal Z; Jones SA; Soran H
    Orphanet J Rare Dis; 2021 Feb; 16(1):107. PubMed ID: 33639994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: A single center experience in Taiwan.
    Pan YW; Tsai MC; Yang CY; Yu WH; Wang B; Yang YJ; Chou YY
    Mol Genet Metab Rep; 2023 Mar; 34():100957. PubMed ID: 36873248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic lipid profile in patients with Niemann-Pick disease type B: What treatment strategies?
    Maines E; Franceschi R; Rizzardi C; Deodato F; Piccoli G; Gragnaniello V; Burlina A; Soffiati M
    J Clin Lipidol; 2022; 16(2):143-154. PubMed ID: 35181260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology.
    Kaddi CD; Niesner B; Baek R; Jasper P; Pappas J; Tolsma J; Li J; van Rijn Z; Tao M; Ortemann-Renon C; Easton R; Tan S; Puga AC; Schuchman EH; Barrett JS; Azer K
    CPT Pharmacometrics Syst Pharmacol; 2018 Jul; 7(7):442-452. PubMed ID: 29920993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
    Pulikottil-Jacob R; Ganz ML; Fournier M; Petruski-Ivleva N
    Adv Ther; 2023 May; 40(5):2234-2248. PubMed ID: 36897522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).
    Wasserstein M; Dionisi-Vici C; Giugliani R; Hwu WL; Lidove O; Lukacs Z; Mengel E; Mistry PK; Schuchman EH; McGovern M
    Mol Genet Metab; 2019 Feb; 126(2):98-105. PubMed ID: 30514648
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.